Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (9), 1291-1299
- https://doi.org/10.1016/j.ejca.2005.03.005
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsAnnals of Oncology, 2005
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Clinical Significance of Angiogenesis in Gastrointestinal CancersAnnals of Surgery, 2003
- Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trialsDrug Resistance Updates, 2000
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Myocardial perfusion modeling using MRIMagnetic Resonance in Medicine, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Tumour blood flow: measurement and manipulation for therapeutic gainCancer Treatment Reviews, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971